MXCT Stock Overview
A life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MaxCyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£4.77 |
| 52 Week High | UK£5.55 |
| 52 Week Low | UK£2.45 |
| Beta | 1.07 |
| 1 Month Change | 22.94% |
| 3 Month Change | -0.42% |
| 1 Year Change | 25.20% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 192.64% |
Recent News & Updates
Shareholder Returns
| MXCT | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 2.8% | 4.3% | 2.3% |
| 1Y | 25.2% | 11.1% | 26.8% |
Return vs Industry: MXCT exceeded the US Life Sciences industry which returned 10.4% over the past year.
Return vs Market: MXCT underperformed the US Market which returned 27.2% over the past year.
Price Volatility
| MXCT volatility | |
|---|---|
| MXCT Average Weekly Movement | 8.0% |
| Life Sciences Industry Average Movement | 7.0% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: MXCT has not had significant price volatility in the past 3 months.
Volatility Over Time: MXCT's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 143 | Maher Masoud | www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte, Inc. Fundamentals Summary
| MXCT fundamental statistics | |
|---|---|
| Market cap | US$501.18m |
| Earnings (TTM) | -US$36.57m |
| Revenue (TTM) | US$44.05m |
11.1x
P/S Ratio-13.4x
P/E RatioIs MXCT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MXCT income statement (TTM) | |
|---|---|
| Revenue | US$44.05m |
| Cost of Revenue | US$5.15m |
| Gross Profit | US$38.91m |
| Other Expenses | US$75.48m |
| Earnings | -US$36.57m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 88.32% |
| Net Profit Margin | -83.00% |
| Debt/Equity Ratio | 0% |
How did MXCT perform over the long term?
See historical performance and comparison